Has Vishal Khemlani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,232,014 in general payments to Vishal Khemlani, MD across 984 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vishal Khemlani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vishal Khemlani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vishal Khemlani, MD

Pain Medicine · Tualatin, ORNPI 1912346461

Payments from drug & device makers

$1,232,014in general payments, 2019–2025

Across 984 payments — averaging $1252.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Nalu Medical, Inc.$944K
Vertos Medical, Inc.$137K
Stryker$80K
Abbott$35K
Biotronik NRO, Inc.$12K
Nevro Corp.$10K
plus $14K from 24 others

$58in research payments, 2019–2025

Across 1 payment — averaging $58.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Saluda Medical Americas, Inc.$58

What the payments were for

Consulting fees$234,66770%
Speaking & faculty fees$22,2707%
Travel & lodging$45,49913%
Food & beverage$35,10310%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Nalu Medical, Inc.	190	$944,456
Vertos Medical, Inc.	210	$136,998
Stryker	89	$79,563
Abbott	180	$35,485
Biotronik NRO, Inc.	90	$12,107
Nevro Corp.	82	$9,552
Boston Scientific	69	$4,646
Biotronik Inc.	2	$3,877
Vertiflex, Inc.	13	$2,553
Medtronic	9	$803
Painteq LLC	3	$224
Saluda Medical Americas, Inc.	5	$215
Globus Medical	4	$170
Lenoss Medical Inc	1	$169
SPR Therapeutics, Inc	2	$155
Cerapedics Inc.	2	$138
Spinal Simplicity, LLC	3	$136
AbbVie(2 entities)	7	$134
Relievant Medsystems, Inc.	2	$111
Si-bone, Inc.	2	$108
Stimwave Technologies Incorporated	2	$105
Radius Health, Inc.	3	$70
Avanos Medical	3	$52
Merit Medical Systems Inc	4	$49
Pfizer	2	$39
Ipsen Biopharmaceuticals, Inc	1	$27
Stratus Medical, LLC	1	$25
Biohaven Pharmaceutical Holding Company Ltd.	1	$21
GRT US Holding, Inc.	1	$14
Johnson & Johnson	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

mild Device Kit$197,914
Nalu Neurostimulation System$48,473
PROCLAIM$30,936
OPTABLATE$24,335
SPINEJACK$13,710
OMNICURVE$12,000
Prospera$9,872
Omnia$4,853
Superion ISS$2,364
SPECTRA WAVEWRITER$2,019
Senza Spinal Cord Stimulation System$1,898
IVS - VERTEBRAL AUGMENTATION PRODUCTS$908
Senza$782
INTELLIS ADAPTIVESTIM$378
Proclaim Family of SCS IPGs$272
OsteoPearl$169
Prodigy Family of SCS IPGs$149
INCEPTIV$145
SUPERION$142
S-Series SCS Leads$140

How this compares

$1,232,014 in reported general payments places this provider in the 95th percentile of 57 pain medicine providers in Oregon.

See all pain medicine providers in Oregon →

Medicare billing

Part B allowed, 2024

$454,822

Medicare patients

339

Services billed

6,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cephalexin	54	$885
Buprenorphine Hcl	26	$523
Gabapentin	38	$492
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	43	$422
Oxycodone Hcl	23	$164
Tramadol Hcl	12	$88
Meloxicam	13	$48
Methocarbamol	11	$45

Paid to pharmacies, not to this prescriber.

Other pain medicine in Tualatin

Robert HerosTualatin$1.8M
Jason AndersonTualatin$17K
Jerry LinTualatin$888
Shawn SillsMedford$1.9M
Joseph SavinoMedford$244K
Sandy ChristiansenPortland$103K
Kimberly MauerPortland$71K
David RussoHood River$49K
Andrew OhPortland$36K
Stuart RosenblumPortland$31K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →